Recent clinical observations and case reports have increasingly associated SGLT-2 inhibitor use with erythrocytosis, characterized by elevated hemoglobin (Hb) and hematocrit (Hct) levels, leading to a rise in hematology referrals for further evaluation [8–13]. This evidence concerns the gene GSTM1 and polycythemia.